Fortis Therapeutics is an immuno-oncology biotech developing a novel antibody-drug conjugate for late-stage multiple myeloma and metastatic castration-resistant prostate cancer. Fortis was founded based on technology exclusively licensed from UCSF and developed in the laboratory of Bin Liu, Ph.D. Fortis is located in COI Pharmaceuticals, Avalon’s Community of Innovation, in San Diego.
Investors 3
Mentions in press and media 3
| Date | Title | Description |
| 29.03.2021 | Fortis Therapeutics Closes $40M Series A | SAN DIEGO, CA, Fortis Therapeutics, an immuno-oncology biotech, announced the close of a $40 million Series A financing. >> Click here for more funding data on Fortis Therapeutics >> To export Fortis Therapeutics funding dat... |
| 29.03.2021 | Fortis Therapeutics Raises $40M in Series A Funding | Fortis Therapeutics, Inc., a San Diego, CA-based immuno-oncology biotech company, closed a $40m Series A financing. Backers included Avalon Ventures, Bregua Corporation, Lilly Asia Ventures, Osage University Partners, and Vivo Capital, as w... |
| 29.03.2021 | Fortis Therapeutics Gets $40M For Cancer Treatments | San Diego-based Fortis Therapeutics, a biotechnology startup developing treatments for late-stage prostate cancer and multiple myeloma, has raised $40M in a Series A financing, the company said on Monday. The funding included Avalon Venture... |